[Form 4] InspireMD, Inc. Insider Trading Activity

Rhea-AI Filing Summary

InspireMD, Inc. reported that Chief Commercial Officer Shane Gleason received an award of 453,390 shares of common stock on January 14, 2026 at a price of $0 per share.

These shares are restricted stock that vest in three equal annual installments on January 14, 2027, January 14, 2028 and January 14, 2029, conditioned on his continued service. After this grant, he directly beneficially owns 1,200,371 shares of InspireMD common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gleason Shane Thomas

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	453,390	$0.00	--

Holdings After Transaction: Common Stock — 1,200,371 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gleason Shane Thomas

(Last) (First) (Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI FL 33126

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		A		453,390(1)	A	$0	1,200,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2029, subject to the Reporting Person's continued service.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Michael Lawless, Attorney-in-Fact for Shane Gleason	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InspireMD (NSPR) disclose in this Form 4?

The company disclosed that Chief Commercial Officer Shane Gleason received an award of 453,390 shares of InspireMD common stock on January 14, 2026, reported as an acquisition coded "A" at a price of $0 per share.

How many InspireMD (NSPR) shares does Shane Gleason hold after this award?

Following the reported transaction, Shane Gleason beneficially owns 1,200,371 shares of InspireMD common stock in direct ownership.

What are the vesting terms of the 453,390 InspireMD restricted shares?

The 453,390 shares of common stock are restricted stock that vest in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2029, subject to Mr. Gleason’s continued service.

Is this InspireMD (NSPR) Form 4 transaction a purchase or an award?

The Form 4 reports an acquisition coded "A" at $0 per share, indicating an equity award of restricted stock to the executive rather than an open-market purchase.

What is Shane Gleason’s role at InspireMD (NSPR) according to this filing?

The reporting person, Gleason Shane Thomas, is identified as an officer of InspireMD, serving as the company’s Chief Commercial Officer, and is not listed as a director or 10% owner.

Are the reported InspireMD (NSPR) shares held directly or indirectly?

The Form 4 indicates that the 1,200,371 shares owned after the transaction are held with direct (D) ownership, with no separate indirect ownership entity described.